Wealthcare Advisory Partners’s abrdn Life Sciences Investors HQL Stock Holding History

Wealthcare Advisory Partners’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$238K	Buy	11,876 +361	+3%	+$6.38K	﹤0.01%	972
2026 Q1	$187K	Buy	11,515 +702	+6%	+$11.7K	﹤0.01%	1028
2025 Q4	$181K	Hold	10,813	–	–	﹤0.01%	1029
2025 Q3	$168K	Buy	10,813 +316	+3%	+$4.33K	﹤0.01%	982
2025 Q2	$134K	Buy	10,497 +196	+2%	+$2.42K	﹤0.01%	946
2025 Q1	$131K	Buy	+10,301	New	+$139K	﹤0.01%	882

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Wealthcare Advisory Partners's HQL Position: Q2 2026 in Review

Wealthcare Advisory Partners increased its abrdn Life Sciences Investors (HQL) stake by 3.1% in Q2 2026, buying an estimated $6.38K and bringing the position to 11,876 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #972.

Wealthcare Advisory Partners first reported a position in HQL in Q1 2025 and has held it in 6 quarters since. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

Wealthcare Advisory Partners held 11,876 shares of abrdn Life Sciences Investors worth $238K as of Q2 2026.
Wealthcare Advisory Partners bought 361 abrdn Life Sciences Investors shares in Q2 2026, an estimated $6.38K.
abrdn Life Sciences Investors made up ﹤0.01% of Wealthcare Advisory Partners's portfolio in Q2 2026, its #972 holding.
Wealthcare Advisory Partners first reported a position in abrdn Life Sciences Investors in Q1 2025 and has held it in 6 quarters since.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2026, filed 9 Jul 2026.